title: The role of the outpatient clinic in chemotherapy for patients with unresectable or recurrent gastric cancer.
abstract: BACKGROUND
  Recently, outpatient chemotherapy centers have become popular in Japan. To clarify the actual conditions of outpatient clinics, we surveyed entire clinical courses of chemotherapy in patients with unresectable or recurrent gastric cancer.
  
  
  METHODS
  From the medical records of 64 patients with unresectable or recurrent gastric cancer with no prior chemotherapy, we obtained data on overall survival, non-hospitalized survival, the number of and reasons for attendance at the outpatient clinic and hospitalization, and medical conditions at discharge.
  
  
  RESULTS
  The median follow-up time was 520 days, the median survival time was 353 days, and the median non-hospitalized survival time was 282 days. Patients attended the outpatient clinic 1917 times in total; 145 (8%) of these were unplanned visits for accidental disease, disease progression, or toxicity. Patients were hospitalized 291 times in total: 110 (38%) of hospitalizations were unplanned or emergencies because of disease progression or toxicity. Patients were discharged 290 times in total; in 56 of these discharges (19%) unresolved medical problems remained, such as toxicity, total parenteral nutrition, or symptoms related to cancer. Three patients (5%) died from treatment-related leucopenia and thrombocytopenia.
  
  
  CONCLUSIONS
  Patients with unresectable and recurrent gastric cancer were treated at outpatient clinics for periods up to 80% longer than the entire clinical course of chemotherapy. However, there were some unplanned or emergency hospitalizations and some patients still experienced medical problems at discharge. The role of the outpatient clinic is very important to chemotherapy for patients with unresectable or recurrent gastric cancer.
authors.affiliation: Division of Gastrointestinal Oncology and Endoscopy, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. k.yamazaki@scchr.jp
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yamazaki
authors.forename: Narikazu
authors.initials: N
authors.lastname: Boku
authors.forename: Kaoru
authors.initials: K
authors.lastname: Shibamoto
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Yasui
authors.forename: Akira
authors.initials: A
authors.lastname: Fukutomi
authors.forename: Takayuki
authors.initials: T
authors.lastname: Yoshino
authors.forename: Shuichi
authors.initials: S
authors.lastname: Hironaka
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Onozawa
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Otake
authors.forename: Noriaki
authors.initials: N
authors.lastname: Hasuike
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Matsubayashi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Inui
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ono
mesh_terms: D000328:Adult; D000368:Aged; D000554:Ambulatory Care Facilities; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002173:Cancer Care Facilities; D004632:Emergency Medical Services; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents